GH
$88.75
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
Recent News
Here’s Why Artisan Small Cap Fund Bets on Guardant Health (GH)
Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Small Cap Fund”. A copy of the letter can be downloaded here. The Fund seeks to invest in companies that possess franchise characteristics, with strong earnings trajectories, and are trading at a discount to the estimated private market value. Despite strong results […]
Guardant Health Touts Quest Deal for Shield, Guardant360 Growth and FDA Milestones at Leerink Conference
Guardant Health (NASDAQ:GH) executives highlighted new commercial initiatives for its Shield colorectal cancer screening test, continued growth drivers for its Guardant360 therapy selection franchise, and upcoming milestones tied to regulatory and reimbursement pathways during a conference discussio
Guardant Health Touts Hypergrowth in Guardant360, Reveal MRD and Shield CRC at Barclays Conference
Guardant Health (NASDAQ:GH) executives used a Barclays discussion to outline growth drivers across treatment selection, minimal residual disease (MRD) testing, and colorectal cancer (CRC) screening, while addressing investor questions on clinical utility, reimbursement, and commercial execution. Tr
Assessing Guardant Health (GH) Valuation As Shield Screening Momentum Builds With FDA Approval And Nationwide Tour
Guardant Health (GH) just kicked off its Shield Across America mobile tour, taking its FDA approved Shield blood test for primary colorectal cancer screening directly into more than 100 communities across the country. See our latest analysis for Guardant Health. The Shield Across America tour sits against a mixed share price backdrop, with a 1 day share price return of 1.75% but a 30 day share price return decline of 18.46%. At the same time, the 1 year total shareholder return of 99.32% and...
Shield Progress Draws Attention To Guardant Health’s Valuation And Risks
Guardant Health’s Shield blood-based colorectal cancer test was recently included in updated National Comprehensive Cancer Network screening guidelines. A new national survey of Americans aged 45 and over shows strong support for broader insurance coverage of blood-based colorectal cancer screening. The company has launched the Shield Across America mobile tour to expand access to blood-based screening across the country, with a focus on underserved communities. Guardant Health...